CM
CRL icon

Castleark Management’s Charles River Laboratories CRL Stock Holding History

Castleark Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.8M Buy
39,435
+7,190
+22% +$1.33M 0.23% 114
2025
Q4 		$6.43M Buy
32,245
+980
+3% +$178K 0.19% 132
2025
Q3 		$4.89M Buy
+31,265
New +$4.97M 0.14% 148
2023
Q1 		– Sell
-4,220
Closed -$920K – 285
2022
Q4 		$920K Buy
+4,220
New +$922K 0.05% 202
2020
Q3 		– Sell
-39,670
Closed -$6.92M – 350
2020
Q2 		$6.92M Sell
39,670
-12,250
-24% -$1.96M 0.3% 99
2020
Q1 		$6.55M Buy
+51,920
New +$7.79M 0.39% 72
2017
Q4 		– Sell
-5,010
Closed -$541K – 410
2017
Q3 		$541K Hold
5,010
– – 0.02% 305
2017
Q2 		$507K Buy
+5,010
New +$461K 0.02% 306

Other funds holding CRL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Castleark Management's CRL Position: Q1 2026 in Review

Castleark Management increased its Charles River Laboratories (CRL) stake by 22% in Q1 2026, buying an estimated $1.33M and bringing the position to 39,435 shares worth $6.8M. The position accounts for 0.23% of the portfolio, ranked #114.

Castleark Management first reported a position in CRL in Q2 2017 and has held it in 8 quarters since. The position peaked at $6.92M in Q2 2020. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Castleark Management held 39,435 shares of Charles River Laboratories worth $6.8M as of Q1 2026.
  • Castleark Management bought 7,190 Charles River Laboratories shares in Q1 2026, an estimated $1.33M.
  • Charles River Laboratories made up 0.23% of Castleark Management's portfolio in Q1 2026, its #114 holding.
  • Castleark Management first reported a position in Charles River Laboratories in Q2 2017 and has held it in 8 quarters since.
  • Castleark Management's Charles River Laboratories position peaked at $6.92M in Q2 2020.
  • 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Castleark Management's 13F filing for Q1 2026, filed 15 May 2026.